Albert Font

3PUBLICATIONS
18CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Apr 29, 2025
Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.

Juan F Rodríguez-Moreno, Guillermo de Velasco, Carlos Álvarez-Fernández

|Dec 15, 2023
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).

Albert Font, Begona Mellado, Miguel A Climent

|Feb 10, 2016
Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II-III esophageal carcinoma.

M Caro, A Font, S Comas

Pageof 1

Frequent Collaborators

1 joint publications

Francisco X Real

1 joint publications

Juan F Rodríguez-Moreno

1 joint publications

Guillermo de Velasco

1 joint publications

Carlos Álvarez-Fernández